Global pharmaceutical leader Lupin Limited has been ranked 318th on TIME and Statista's World's Most Sustainable Companies 2026 list. The company debuted on the list, which selected 750 companies from over 5,000 of the world's largest and most influential organizations. This recognition underscores Lupin's commitment to environmental stewardship, responsible business practices, strong governance, and positive social impact.

The ranking assessed companies across more than 20 sustainability indicators, covering sustainability commitments, reporting transparency, and environmental and social performance. Lupin is among 16 Indian companies included in this year's global ranking. The evaluation process highlights the company's sustained efforts to integrate ESG priorities across its global operations and create long-term value for patients, communities, and stakeholders.

Ramesh Swaminathan, Executive Director, Global CFO, Head of IT and API Plus SBU, Lupin, stated that the inclusion marks an important recognition for the company. He emphasized that sustainability is central to driving performance while advancing the company's purpose. Swaminathan reaffirmed commitments to accelerating climate transition, strengthening governance and transparency, scaling renewable energy, and integrating ESG enterprise-wide.

The recognition builds on Lupin's strong ESG performance metrics. The company holds CDP's highest 'A' leadership rating for both Climate Change and Water Security. Additionally, Lupin achieved an S&P Global Corporate Sustainability Assessment score of 91 in 2025.

Key Recognition Details

Lupin has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey. The EIR has been issued with a Voluntary Action Indicated (VAI) classification, confirming compliance with manufacturing standards. This outcome is critical for the company as it ensures uninterrupted supply from the facility to the U.S. market, reinforcing its commitment to quality and operational excellence.

The inspection at the Somerset facility was conducted from April 13, 2026, to April 17, 2026. Following the review, the U.S. FDA determined that any observations made during the inspection do not warrant regulatory action. Nilesh Gupta, Managing Director, Lupin, stated that the outcome reflects the company's unwavering commitment to quality, compliance, and operational excellence.

Regulatory Outcome at Somerset Facility

The issuance of an EIR with VAI status indicates that the U.S. FDA has completed its review of the facility inspection. VAI is one of the most favorable classifications a facility can receive following a U.S. FDA inspection.

Significance of VAI Classification

A VAI classification from the U.S. FDA signifies that, while observations may have been noted during the inspection, they are not considered significant enough to require mandatory corrective action by the company. This outcome is widely regarded as a positive regulatory signal for pharmaceutical manufacturers operating in the U.S. market. The Somerset facility's receipt of this status underscores Lupin's compliance posture at this manufacturing site.